O
Description
Biopharmaceutical company founded in 2009 by Stefan Ogrodzinski, spun out from BioStatus. Develops hypoxia-activated pro-drugs to treat therapy-resistant cancer cells in low-oxygen tumor areas. Lead compound: OCT1002. Presence in Kraków (Poland) and Leicestershire (UK). ~6 employees.